【摘要】 目的 觀察不同劑量的舒芬太尼用于剖宮產術后硬膜外自控鎮痛的效果比較。 方法 將2009年4-11月60例硬膜外麻醉下行剖宮產手術術后的患者隨機分為三組，術后鎮痛液A組采用0.125%羅哌卡因復合0.3 μg/mL舒芬太尼；B組為0.125%羅哌卡因復合0.4 μg/mL舒芬太尼；C組0.125%羅哌卡因復合0.5 μg/mL舒芬太尼，觀察三組患者的術后鎮痛效果（視覺模擬法評分，即VAS評分）及不良反應。 結果 A組VAS評分高于B組和C組，B組VAS評分高于C組（Plt;0.05）。三組患者術后惡心嘔吐、運動阻滯、嗜睡及腸蠕動抑制等并發癥無統計學差異（Pgt;0.05）。 結論 0.125%羅哌卡因復合0.5 μg/mL舒芬太尼以4 mL/h持續輸注用于剖宮產術后患者自控硬膜外鎮痛術后疼痛VAS評分最小，患者鎮痛滿意度最高。【Abstract】 Objective To observe the effect of postoperative patient-controlled epidural analgesia (PCEA) with three different doses of sufentanil combined with 0.125% ropivacaine after cesarean section. Methods Data was collected from April 2009 to November 2009. Sixty patients after cesarean section under continuous epidural anesthesia were randomly divided into three different groups.Group A was given sufentanil 0.3 μg/mL and 0.125% ropivacaine for PCEA, group B was given sufentanil 0.4 μg/mL and 0.125% ropivacaine, group C was given sufentanil 0.5 μg/mL and 0.125% ropivacaine. The analgesia effects were evaluated by the visual analogue scales (VAS). Side effects were also recorded. Results The VAS scores were significantly the highest in group A than that in group B and group C, the VAS scores in group B were higher than that in group C (Plt;0.05). The incidence of side effects, such as postoperative nausea and vomiting, lethargy, and pruritus, was not significant among the three groups (Pgt;0.05). Conclusion 0.5 μg/ mL sufentanil and 0.125% ropivacaine recommended for PCEA with background 4 mL/h is safe and effective for patients after cesarean section.
Minimally invasive cardiac surgeries are the trend in the future. Among them, robotic cardiac surgery is the latest iteration with several key-hole incision, 3-dimentional visualization, and articulated instrumentation of 7 degree of ergonomic freedom for those complex procedures in the heart. In particular, robotic mitral valve surgery, as well as coronary artery bypass grafting, has evolved over the last decade and become the preferred method at certain specialized centers worldwide because of excellent results. Other cardiac procedures are in various stages of evolution. Stepwise innovation of robotic technology will continue to make robotic operations simpler, more efficient, and less invasive, which will encourage more surgeons to take up this technology and extend the benefits of robotic surgery to a larger patient population.
ObjectiveTo systematically evaluate the medication adherence of patients with hypertension treated with single-pill combinations (SPC) compared with free combination therapy (FEC). MethodsThe PubMed, Embase, Cochrane Library, Web of Knowledge, CBM, WanFang Data, and CNKI databases were electronically searched to collect cohort studies and randomized controlled trials (RCTs) related to the objects from inception to March 2025. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed by using R 4.3.3 software. ResultsA total of 21 studies were included, comprising 4 RCTs and 17 cohort studies, involving 461 030 patients. Meta-analysis showed that SPC therapy significantly improved medication adherence compared with FEC in terms of proportion of days covered (PDC) (OR=2.53, 95%CI 1.67 to 3.82, P<0.01) and medication possession ratio (MPR) (OR=2.05, 95%CI 1.43 to 2.94, P=0.02), with statistically significant differences. However, there was no statistically significant difference in blood pressure reduction between SPC and FEC for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) (P>0.05). ConclusionCurrent evidence shows that SPC can improve medication adherence in patients with hypertension. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion.